Global Central Nervous System Partnering 2010-2016: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2016
No. of pages: 600
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Central Nervous System Partnering 2010 to 2016 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Central Nervous System partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Central Nervous System partnering agreement structure

Central Nervous System partnering contract documents

Top Central Nervous System deals by value

Most active Central Nervous System dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.

The report presents financial deal terms values for Central Nervous System deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Central Nervous System dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Central Nervous System dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Central Nervous System deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Central Nervous System dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Central Nervous System deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2010. The chapter is organized by specific Central Nervous System therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Central Nervous System partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Central Nervous System partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Central Nervous System technologies and products.

Report scope

Global Central Nervous System Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Central Nervous System trends and structure of deals entered into by leading companies worldwide.

Global Central Nervous System Partnering 2010 to 2016 includes:

Trends in Central Nervous System dealmaking in the biopharma industry since 2010

Analysis of Central Nervous System deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Central Nervous System deal contract documents

Comprehensive access to over 3500 Central Nervous System deal records

The leading Central Nervous System deals by value since 2010

Most active Central Nervous System dealmakers since 2010

The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.

In Global Central Nervous System Partnering 2010 to 2016, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Central Nervous System Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 1,500 central nervous system deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Central Nervous System Partnering 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of Central Nervous System deal trends since 2010

Access Central Nervous System deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Central Nervous System partner companies

Comprehensive access to over 750 links to actual Central Nervous System deals entered into by the world's biopharma companies

Indepth review of Central Nervous System deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Central Nervous System opportunities

Uncover companies actively partnering Central Nervous System opportunities

Global Central Nervous System Partnering 2010-2016: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Central Nervous System dealmaking
2.1. Introduction
2.2. Central Nervous System partnering over the years
2.3. Central Nervous System partnering by deal type
2.4. Central Nervous System partnering by industry sector
2.5. Central Nervous System partnering by stage of development
2.6. Central Nervous System partnering by technology type
2.7. Central Nervous System partnering by therapeutic indication

Chapter 3 -Financial deal terms for Central Nervous System partnering
3.1. Introduction
3.2. Disclosed financials terms for Central Nervous System partnering
3.3. Central Nervous System partnering headline values
3.4. Central Nervous System deal upfront payments
3.5. Central Nervous System deal milestone payments
3.6. Central Nervous System royalty rates

Chapter 4 - Leading Central Nervous System deals and dealmakers
4.1. Introduction
4.2. Most active in Central Nervous System partnering
4.3. List of most active dealmakers in Central Nervous System
4.4. Top Central Nervous System deals by value

Chapter 5 - Central Nervous System contract document directory
5.1. Introduction
5.2. Central Nervous System partnering deals where contract document available

Chapter 6 - Central Nervous System dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Central Nervous System therapeutic target

Appendices
Appendix 1 - Directory of Central Nervous System deals by company A-Z 2010 to 2016
Appendix 2 - Directory of Central Nervous System deals by deal type 2010 to 2016
Appendix 3 - Directory of Central Nervous System deals by stage of development 2010 to 2016
Appendix 4 - Directory of Central Nervous System deals by technology type 2010 to 2016
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Tables and Figures

Figure 1: Central Nervous System partnering since 2010
Figure 2: Central Nervous System partnering by deal type since 2010
Figure 3: Central Nervous System partnering by industry sector since 2010
Figure 4: Central Nervous System partnering by stage of development since 2010
Figure 5: Central Nervous System partnering by technology type since 2010
Figure 6: Central Nervous System partnering by indication since 2010
Figure 7: Central Nervous System deals with a headline value
Figure 8: Central Nervous System deals with upfront payment values
Figure 9: Central Nervous System deals with milestone payment
Figure 10: Central Nervous System deals with royalty rates
Figure 11: Active Central Nervous System dealmaking activity- 2010 to 2016
Figure 12: Top Central Nervous System deals by value since 2010
  • Global Luxury Apparels Market To Do Well Owing To Numerous International Brands
    The global luxury apparels market is fired by the intensifying number of fashion marques and many designers getting wide-ranging clienteles in the form of cost-effective products. The global luxury apparels market was at US$1, 8842.69 million in 2015 and is forecast to reach US$60,793.7 million by the end of 2024. This segment of luxury goods [...]
  • Global Health and Wellness Market Boosted By Organic Products and Wearables
    Healthcare has constantly been a profitable area where buyers spend belligerently. But now, with increasing disposable earnings amid the city population and ground-breaking approaches and innovative products being developed, the overall health and wellness market is estimated for a healthy prospect. The health and wellness market is presently very dynamic owing to growing alertness amongst [...]
  • Increasing New Outlets And Striking Offers To Drive Global Pizza Market
    The global pizza market is predicted to grow at a steady CAGR of about 3% by 2020. Pizza has been gaining massive acceptance globally in the last few years. Consequently, the global pizza market is anticipated to observer considerable progress in the coming years. The growing number of pizzerias is one of the major elements [...]
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Gingivitis - Pipeline Review, H2 2016
    Published: 23-Nov-2016        Price: US 2000 Onwards        Pages: 33
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gingivitis - Pipeline Review, H2 2016, provides an overview of the Gingivitis (Mouth And Dental Disorders) pipeline landscape.Gingivitis is an inflammation of the gums, usually caused by a bacterial infection. Symptoms include sensitive teeth, pus between teeth and gums, loose teeth, gums that are red, tender, or swollen. Risk factors include diabetes, smoking or chewing tobacco, broken fillings, compromised i......
  • United States Dental Acrylics Market by Manufacturers, Type and Application, Forecast to 2021
    Published: 07-Nov-2016        Price: US 4480 Onwards        Pages: 109
    Denture acrylic resins are used for the base of dentures. They may be traditional heat-cured, cold-cured or self-cured. Color stability is important as well, as is strength, durability and comfort. Preference of the dental technician fabricating the dentures will ultimately be the deciding factor to which denture acrylic resin is chosen.Scope of the Report:This report focuses on the Dental Acrylics in United States market. This report categorizes the market based on manufa......
  • Dental Pain-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Dental Pain-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Dental Pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundi......
  • Gingivitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Gingivitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Gingivitis Report is to understand the market and pipeline status of the drugs around the Gingivitis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipel......
  • Periodontal Disease-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Periodontal Disease-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Periodontal Disease. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acq......
  • Periodontitis-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Periodontitis-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Periodontitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, f......
  • Dental Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Dental Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Dental Pain Report is to understand the market and pipeline status of the drugs around the Dental Pain to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pi......
  • Dental Pain-API Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • Gingivitis-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Gingivitis-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Gingivitis. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, funding......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs